Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Gain Therapeutics Inc. Common Stock
GANX | US
2.14
USD0.25
13.23%
GANX | US
Loading StockChartView...
About Gain Therapeutics Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
15/04/2026
Close
2.14
Open
1.91
High
2.15
Low
1.88
Gain Therapeutics Inc. a biotechnology company researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites restore protein folding and treat disease. Its lead product candidate includes GT-02287 for the treatment of GBA1 Parkinson's disease. In addition the company is developing structurally targeted allosteric regulator candidates to treat various diseases including Morquio B GM1 gangliosidosis (GM1) neuronopathic Gaucher disease GBA1 Parkinson's Krabbe and Mucopolysaccharidosis type 1 diseases. Gain Therapeutics Inc. was founded in 2017 and is headquartered in Bethesda Maryland.
View LessGANX | US
Risk
112.4
Sharpe
0.20
Luna's Score
49/100
Recommendation
Hold
Luna says (GANX | US)
What's Working
Strength based on increasing price with high volume
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
78.2%1 month
112.4%3 months
119.5%6 months
135.8%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
6.00
Debt to equity
0.07
Debt to assets
0.04
Ent. to EBITDA
-1.55
Ent. to rev.
138.34
PEG
-
Other Fundamentals
EBITDA
-21.82M
MarketCap
54.65M
MarketCap(USD)
54.65M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-100.00
Ret. on equity
-188.83
Short ratio
1.97
Short perc.
2.69
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.43
Range1M
0.98
Range3M
1.46
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.11
Price X volume
1.68M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.55 | 0.53 | Cheaper |
| Ent. to Revenue | 138.34 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 6.00 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 119.54 | 72.80 | Riskier |
| Debt to Equity | 0.07 | -1.23 | Expensive |
| Debt to Assets | 0.04 | 0.25 | Cheaper |
| Market Cap | 54.65M | 3.66B | Emerging |
